EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synaptic Potentiation in Hippocampus by eEF2K Inhibitor A484954

Qian Yang, Tian Li, Hannah M Jester, Qiang Su, Xueyan Zhou, Alexey G Ryazanov, Tao Ma

Hippocampus · 2026-05 · 36 (3)

DOI: 10.1002/hipo.70091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hippocampus, online erschienen am 27.03.2026. Verfasst von Qian Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Elongation Factor 2 Kinase, Long-Term Potentiation, Hippocampus. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An important mechanism controlling protein synthesis is through phosphorylation of the eukaryotic elongation factor 2 (eEF2) by its kinase eEF2K. Hyperphosphorylation of eEF2 is linked to many neuronal diseases characterized by cognitive impairments. Consistently, recent studies show that the inhibition of the eEF2K signaling via genetic or pharmacological approaches can alleviate synaptic failure and dementia syndromes in mouse models of Alzheimer's disease (AD) and related dementias (ADRDs). One commonly used tool to study eEF2K signaling is A‐484954 (or AG), a small molecule compound that is considered a highly selective and potent eEF2K antagonist. Here we reported that the AG compound (at three doses) can induce chemical long‐term potentiation (LTP) in acute hippocampal slices from mice. Taking advantage of two transgenic mouse models with eEF2K knockout or overexpression, we further demonstrated that eEF2K‐independent mechanisms contribute to chemical LTP induced by AG (dose‐dependent). Our data suggest cautious interpretation of findings on neuronal effects of eEF2K inhibitors such as AG. Future investigations are warranted to elucidate the detailed molecular mechanisms underlying the effects of AG compound and other eEF2K inhibitors on synaptic and cognitive function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Elongation Factor 2 KinaseLong-Term PotentiationHippocampusAnimalsMice, TransgenicMice, KnockoutDose-Response Relationship, DrugMiceMaleMice, Inbred C57BLExcitatory Postsynaptic PotentialsPyridinesPyrimidines

Stichwörter der Autor:innen

LTPeEF2KeEF2K inhibitorshippocampusprotein synthesissynapses

Substanzen

Elongation Factor 2 KinaseEef2k protein, mouseA-484954PyridinesPyrimidines

Autor:innen und Institutionen

  • Department of Internal Medicine, Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.
  • Department of Translational Neuroscience, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

Förderung

  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Yang, Q., Li, T., Jester, H. M., Su, Q., Zhou, X., Ryazanov, A. G., & Ma, T. (2026). Synaptic Potentiation in Hippocampus by eEF2K Inhibitor A484954. Hippocampus, 36(3). https://doi.org/10.1002/hipo.70091

Vancouver

Yang Q, Li T, Jester HM, Su Q, Zhou X, Ryazanov AG, et al. Synaptic Potentiation in Hippocampus by eEF2K Inhibitor A484954. Hippocampus. 2026;36(3). doi:10.1002/hipo.70091

BibTeX
@article{Yang2026,
  author = {Yang, Qian and Li, Tian and Jester, Hannah M and Su, Qiang and Zhou, Xueyan and Ryazanov, Alexey G and Ma, Tao},
  title = {Synaptic Potentiation in Hippocampus by eEF2K Inhibitor A484954},
  journal = {Hippocampus},
  year = {2026},
  volume = {36},
  number = {3},
  doi = {10.1002/hipo.70091}
}
Kostenlos starten →